Meet the Team »  Radiation Oncology »  Alexander R. Gottschalk, M.D., Ph.D.
Alexander R. Gottschalk, M.D., Ph.D.

Alexander R. Gottschalk, M.D., Ph.D.

Professor of Radiation Oncology
Director, CyberKnife Radiosurgery Program
Department of Radiation Oncology

Contact Information

Department of Radiation Oncology
Box 1708, 1600 Divisadero St, MZ Bldg R H1031
San Francisco, CA. 94143 - 1708
Phone: 415-353-7175
Fax 415-353-9883
agottschalk@radonc.ucsf.edu
Open Popup
  • 1988 University of Chicago BA Chemistry
  • 1994 University of Chicago PhD Pathology
  • 1996 University of Chicago MD Medicine
  • 1996-1997 Kaiser Permanente Medical Center, Santa Clara, CA Intern Internal Medicine
  • 1997-2001 UCSF Resident Radiation Oncology
  • 01/00-04/00 UCSF Chief Resident Radiation Oncology
  • 1997-2001 UCSF Residency in Radiation Oncology
  • 1996-1997 Kaiser Internal Medicine Internship
  • American Board of Radiology
  • Thoracic Oncology Program
  • Department of Radiation Oncology
  • Helen Diller FamilyComprehensive Cancer Center
  • Sarcoma Program
  • Brain and Spinal Tumors
  • Bronchioloalveolar Carcinoma (BAC)
  • CyberKnife Irradiation for Lung and Skull Base
  • Esophageal Cancer
  • External-beam Radiation
  • Intensity-modulated radiation therapy (IMRT)
  • Non-Small Cell Lung Cancer
  • Sarcoma
  • Small-Cell Lung Cancer
  • Stereotactic Lung Radiotherapy (SBRT)
  • Image-guided and adaptive radiation therapy
  • Radiation in combination with chemotherapy and targeted agents
  • Radiation sensitizers and protectors

Dr. Alexander Gottschalk, an expert in radiation treatment, is director of the UCSF Cyberknife Radiosurgery Program. Using the Cyberknife, Gottschalk treats cancer of the brain and spine; breast, chest and lung; abdomen; kidney; and pelvis. In addition, he treats urologic cancer such as bladder and prostate cancer; gastrointestinal cancer such as pancreas cancer; soft tissue tumors such as sarcoma and thoracic cancer such as lung cancer, using other radiation treatments.

Gottschalk earned a medical degree and Ph.D. at the University of Chicago and completed a residency in radiation oncology at UCSF Medical Center. He is the recipient of numerous awards and grants, including the National Institutes of Health National Research Service Award, Medical Scientist Training Program Fellowship, UCSF Helen Diller Family Comprehensive Cancer Center Clinical Investigator Research Program Grant, the RSNA Scholar award and the ASTRO Junior faculty award. He is an associate professor of radiation oncology at UCSF and active in genitourinary research. He is developing clinical trials using inter-operative.

Dr. Gottschalk is involved in a number of clinical research projects. First, he has studied several methods of image-guided radiotherapy (IGRT), including, ultrasound, electronic portal imagining using gold seed fiducial markers and megavoltage cone-beam CT (MVCBCT). His research is one of the first to evaluate prostate bed motion in patients undergoing radiotherapy after prostatectomy. Dr. Gottschalk has investigated the use of MVCBCT for dose calculation and re-calculation as well as a novel high quality, low dose, imaging beam line. The dose re-calculation can be use for dose guided radiation therapy (DGRT).

Second, using the Radiation Oncology clinical database, Dr. Gottschalk has studied: the effectiveness of intraoperative radiation therapy (IORT) in the management of extremity sarcomas and renal cell carcinoma recurrences, permanent seed brachytherapy and high dose-rate brachytherapy (HDR) for the treatment of prostate cancer both as primary therapy and as salvage after radiation failures.

Third, he has been involved as a co-investigator in three trials: a Phase 2, Single-Center, Open-Label phase I/II study to evaluate safety and efficacy and Safety in patients who have resectable esophageal cancer and are treated with neoadjuvant cisplatin, irinotecan (CPT-11), ZD1839 (IRESSA®), and radiotherapy followed by surgical resection; a phase II study of radiation therapy, paclitaxel poliglumex and carboplatin in stage III non-small cell lung cancer; and a phase I/II open-label dose escalation study of anti-CTLA4 antibody with radiation for metastatic hormone refractory prostate cancer.

 Forth, Dr. Gottschalk is involved with several RTOG (Radiation Therapy Oncology Group) studies. These have included several prostate cancer trials that investigate: high-dose vs standard-dose readiation for intermediate-risk prostate cancer; brachytherapy vs external-beam radiation plus brachytherapy for intermediate-risk prostate cancer; and standard fractionation vs hypofractionation for low-risk prostate cancer. Finally, as Director of the CyberKnife Radiosurgery Program Dr. Gottschalk oversees several of the stereotactic body radiosugery (SBRT) trials for lung and prostate cancer. He has a particular interest in the use of CyberKnife SBRT for the treatment of prostate cancer, kidney cancer, and lung cancer.

Most recent publications from a total of 94
  1. Paulsson AK, Yom SS, Anwar M, Pinnaduwage D, Sudhyadhom A, Gottschalk AR, Chang AJ, Descovich M. Respiration-Induced Intraorgan Deformation of the Liver. Technol Cancer Res Treat. 2017 Jan 01; 1533034616687193. View in PubMed
  2. Davis BJ, Taira AV, Nguyen PL, Assimos DG, D'Amico AV, Gottschalk AR, Gustafson GS, Keole SR, Liauw SL, Lloyd S, McLaughlin PW, Movsas B, Prestidge BR, Showalter TN, Vapiwala N. ACR appropriateness criteria: Permanent source brachytherapy for prostate cancer. Brachytherapy. 2017 Mar - Apr; 16(2):266-276. View in PubMed
  3. Zaorsky NG, Showalter TN, Ezzell GA, Nguyen PL, Assimos DG, D'Amico AV, Gottschalk AR, Gustafson GS, Keole SR, Liauw SL, Lloyd S, McLaughlin PW, Movsas B, Prestidge BR, Taira AV, Vapiwala N, Davis BJ. ACR Appropriateness Criteria® external beam radiation therapy treatment planning for clinically localized prostate cancer, part I of II. Adv Radiat Oncol. 2017 Jan-Mar; 2(1):62-84. View in PubMed
  4. Garcia MM, Gottschalk AR, Brajtbord J, Konety BR, Meng MV, Roach M, Carroll PR. Correction: Endoscopic Gold Fiducial Marker Placement into the Bladder Wall to Optimize Radiotherapy Targeting for Bladder-Preserving Management of Muscle-Invasive Bladder Cancer: Feasibility and Initial Outcomes. PLoS One. 2016; 11(10):e0164558. View in PubMed
  5. Woodard GA, Crockard JC, Clary-Macy C, Zoon-Besselink CT, Jones K, Korn WM, Ko AH, Gottschalk AR, Rogers SJ, Jablons DM. Hybrid minimally invasive Ivor Lewis esophagectomy after neoadjuvant chemoradiation yields excellent long-term survival outcomes with minimal morbidity. J Surg Oncol. 2016 Dec; 114(7):838-847. View in PubMed
  6. Zhang L, Johnson J, Gottschalk AR, Chang AJ, Hsu IC, Roach M, Seymour ZA. Receiver operating curves and dose-volume analysis of late toxicity with stereotactic body radiation therapy for prostate cancer. Pract Radiat Oncol. 2017 Mar - Apr; 7(2):e109-e116. View in PubMed
  7. Wahl M, Descovich M, Shugard E, Pinnaduwage D, Sudhyadhom A, Chang A, Roach M, Gottschalk A, Chen J. Interfraction Anatomical Variability Can Lead to Significantly Increased Rectal Dose for Patients Undergoing Stereotactic Body Radiotherapy for Prostate Cancer. Technol Cancer Res Treat. 2017 Apr; 16(2):178-187. View in PubMed
  8. Crehange G, Izaguirre A, Weinberg V, Hsu CC, Gottschalk AR, Hsu IC, Shinohara K, Carroll P, Roach M. Long-term Outcomes Following Radiation Therapy For Prostate Cancer Patients With Lymph Node Metastases at Diagnosis Treated With and Without Surgery. Am J Clin Oncol. 2016 Apr; 39(2):167-72. View in PubMed
  9. Pinnaduwage DS, Descovich M, Lometti MW, Varad B, Roach M, Gottschalk AR. An Evaluation of Robotic and Conventional IMRT for Prostate Cancer: Potential for Dose Escalation. Technol Cancer Res Treat. 2017 Jun; 16(3):267-275. View in PubMed
  10. Anwar M, Weinberg V, Seymour Z, Hsu IJ, Roach M, Gottschalk AR. Outcomes of hypofractionated stereotactic body radiotherapy boost for intermediate and high-risk prostate cancer. Radiat Oncol. 2016 Jan 21; 11:8. View in PubMed
  11. View All Publications
Publications provided by UCSF Profiles, powered by CTSI at UCSF. View profile of Alexander R. Gottschalk, M.D., Ph.D.
Please note: UCSF Profiles publications are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact CTSI for help.

X